Skip to Content


In the US, Sprycel (dasatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Leukemia.

US matches:

UK matches:

Ingredient matches for Sprycel


Dasatinib is reported as an ingredient of Sprycel in the following countries:

  • Australia
  • Belgium
  • Canada
  • Colombia
  • Denmark
  • Egypt
  • Greece
  • Hong Kong
  • Iceland
  • India
  • Israel
  • Lebanon
  • Lithuania
  • Mexico
  • New Zealand
  • Poland
  • Portugal
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Switzerland
  • Taiwan
  • Thailand
  • Tunisia
  • Turkey

Dasatinib monohydrate (a derivative of Dasatinib) is reported as an ingredient of Sprycel in the following countries:

  • Argentina
  • Austria
  • Chile
  • Croatia (Hrvatska)
  • Czech Republic
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Japan
  • Latvia
  • Netherlands
  • Norway
  • Oman
  • Romania
  • Spain
  • Sweden
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.